Rubius Therapeutics
620 Memorial Drive
Suite 100W
Cambridge
Massachusetts
02139
United States
Website: http://www.rubiustx.com/
141 articles about Rubius Therapeutics
-
Rubius Therapeutics’ board of directors has approved a plan to liquidate and dissolve the company, the Massachusetts-based biotech announced in an SEC form 8-K filed Monday.
-
Rubius Therapeutics plans to initiate a large restructuring initiative, which includes laying off 84% of its staff and a possible sale, the company announced Wednesday.
-
Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes
11/2/2022
Rubius Therapeutics, Inc. announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process.
-
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
9/19/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT.
-
Rubius Therapeutics Announces Strategic Update
9/13/2022
Rubius Therapeutics, Inc. announced plans to restructure the Company and align resources to advance its next generation red blood cell-based cell conjugation platform.
-
Rubius is undertaking another restructuring focused on its Red Cell Therapeutics technology that will result in the termination of 75% of its staff and a return to a preclinical starting board.
-
Rubius Therapeutics to Provide Strategic Update
9/12/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY) today announced that the Company plans to provide a strategic update and host an investor teleconference and webcast on Tuesday, September 13, 2022, at 7:30 a.m. EDT.
-
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
8/9/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today reported second quarter 2022 financial results and provided a business update.
-
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
7/26/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open.
-
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
7/14/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Susanne Schaffert, Ph.D., to its board of directors.
-
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
6/22/2022
Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment; Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression Findings Potentially Translatable to Multiple T Cell-Mediated Autoimmune Diseases.
-
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference - June 01, 2022
6/1/2022
Rubius Therapeutics, Inc. announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 2:30 p.m. EDT.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
5/26/2022
Rubius Therapeutics, Inc. (Nasdaq:RUBY), today announced that the Company will present a Trials in Progress poster presentation for its second broad immune stimulation program, RTX-224, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors
5/24/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced the appointment of Noubar Afeyan, Ph.D., co-founder and member of the board of directors of Rubius Therapeutics and chief executive officer of Flagship Pioneering, as chairman of its board of directors.
-
Flagship Pioneering has partnered with Novo Nordisk to build a portfolio of potential treatments for cardiometabolic and rare diseases.
-
Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
5/10/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today reported first quarter 2022 financial results and provided a business update.
-
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
4/26/2022
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced plans to report first quarter financial results on Tuesday, May 10, 2022, before market open.
-
Noubar Afeyan, founder of Flagship Pioneering and Moderna, spoke at an event hosted by the Institute of Global Health Innovation.
-
Shares fell in several life sciences companies at the close of the market Friday on apparently lackluster early data from their respective research projects. We look into each one below: